Stem Cells Could Treat Diabetes If Coaxed Onto That Path
Posted on: Tuesday, 19 July 2005, 00:00 CDT
SAN FRANCISCO - Diabetes is one of the most promising targets of stem cell research. People with this disease have problems with insulin, a hormone in the pancreas that regulates blood sugar levels. Patients have poorly functioning or too few insulin- producing cells, known as beta cells.
"We think that ultimately the way to cure people with diabetes, or at least many patients with diabetes, is to replace those cells," said Michael German of the University of California-San Francisco's Diabetes Center.
Several clinics worldwide, including the University of California- San Francisco, already do this by transplanting beta cells from cadavers into diabetes patients.
"The problem is, at present we don't have nearly enough cells to do this," German said.
There are more than 150 million people with diabetes and more than a half million new cases each year in the United States alone. But fewer than 5,000 pancreases are available for donation yearly, he said.
"If we had an unlimited supply of these cells, we could treat everybody with diabetes," German said.
He hopes stem cells can help generate that supply.
In normal human development, some stem cells eventually become beta cells. The cells face a series of decisions that lead them down the path to becoming insulin-producing cells or another cell type. To become a beta cell, they must first decide to become part of the gastrointestinal tract, and eventually part of the pancreas, and then part of the pancreas area that contains specialized cells, including beta cells. Finally they must decide to become a beta cell.
German is working on how to coax embryonic stem cells along this path.
"The idea is that if we knew the genes and the signaling pathways that control each of these decisions that we could in fact take embryonic stem cells and drive them specifically to make these decisions and end up as beta cells."
Source: Sunday Gazette - Mail; Charleston, W.V.
Related Articles
- Boehringer Ingelheim to Commence Phase III Study Investigating the Role of BIBW 2992 as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Mutations
- University of Minnesota's Internationally Recognized Stem Cell Experts Available for Interviews on What Lifting the Federal Funding Restrictions Will Mean to Stem Cell Research and to Patients Who Stand to Benefit
- Stem Cells May Benefit Leukemia Patients
- Stem Cell Transplants Aid Angina Patients
- Data Show Geron's Telomerase Inhibitor Cancer Drug is Active Against Cancer Stem Cells From Multiple Myeloma Patients
- Quigley Pharma Scheduled to Commence Clinical Testing of QR-333, Its Topical Diabetic Peripheral Neuropathy Investigational New Drug; Pharmacokinetics Study at the Diabetes & Glandular Disease Research Center in San Antonio Slated for May 15th Start Date
- Baxter Commences First-Of-Its-Kind, Phase II Adult Stem Cell Trial in U.S. In Patients With Severe Coronary Artery Disease
- Clinical Trial to Begin for Stem Cell Treatment in Heart Patients
- Stem Cell Panel Issues Decision
- Stem Cell Subtype Aids Lung Patients
User Comments (1)
| 1. |
Posted by Rose Black on 12/03/2006, 18:15 i think that they should go on this path. i have type 1 diabetes and if this cure is only for type 2 they should still get on a path for type 1 |

RSS Feeds